Clinical trials: Stage II Skin Cancer
Breast Neoplasms
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
The main objective of the trial is to assess the efficacy of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and…
- Trial name
- NCT03659136
- Testing
- Xentuzumab, Everolimus, Exemestane
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 103 people
- Sponsor
- Boehringer Ingelheim
Estrogen Receptor Status, HER2/Neu Negative
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body.
- Conditions
- Estrogen Receptor Status, HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal
- Trial name
- NCT02860000
- Testing
- Alisertib, Fulvestrant, Laboratory Biomarker Analysis
- Where
- 8 sites in United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Advanced Breast Cancer, HER2-positive Breast Cancer
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
This is a multicenter, international, open-label, single-arm, multicohort, two-stage optimal Simon's design, phase II clinical trial
- Conditions
- Advanced Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- DEBBRAH (NCT04420598)
- Testing
- Trastuzumab deruxtecan
- Where
- 16 sites in Portugal, Spain
- Volunteers
- 41 people
- Sponsor
- MedSIR
PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
This was a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part was to estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the combination of BYL719 and AMG 479 (ganitumab)…
- Trial name
- NCT01708161
- Testing
- BYL719, AMG 479
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Depression
Yoga or Educational Wellness Class for Women With Stage I, Stage II, or Stage III Breast Cancer Undergoing Chemotherapy
RATIONALE: Yoga and wellness classes may reduce fatigue and improve mood, sleep, and quality of life in women receiving chemotherapy for breast cancer.
- Conditions
- Breast Cancer, Depression, Fatigue, Sleep Disorders
- Trial name
- NCT00994279
- Testing
- Yoga, Education
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
The primary objectives are to determine the progression-free survival (PFS) and to evaluate safety of the trastuzumab, bevacizumab and docetaxel regimen.
- Trial name
- NCT00428922
- Testing
- Trastuzumab, Bevacizumab, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Bhuvaneswari Ramaswamy
Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with aromatase inhibitors (AIs) due to the development of musculoskeletal symptoms (MSS).
- Conditions
- Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01824836
- Testing
- anastrozole
- Where
- 2 sites in United States
- Volunteers
- 1,046 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Metastatic Breast Cancer
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer
The purpose of this randomized, Phase 2 open-label study was to assess the response rate of participants with Human Epidermal Growth Factor Receptor 2 (Her2+) locally advanced and/or metastatic breast cancer (not previously…
- Trial name
- NCT00490646
- Testing
- ixabepilone, docetaxel, trastuzumab
- Where
- 19 sites in France, Greece and 3 more
- Volunteers
- 50 people
- Sponsor
- R-Pharm
Breast Cancer
Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer
The drugs FEC 100 (5-fluorouracil, epirubicin, and cyclophosphamide) are one of the approved options to treat Locally Advanced or Primary Metastatic Breast Cancer.
- Trial name
- VPA-FEC100 (NCT01010854)
- Testing
- VPA FEC100
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
This phase IIb trial studies how well alternative dosing of exemestane before surgery works in treating in postmenopausal patients with stage 0-II estrogen positive breast cancer.
- Conditions
- Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- NCT02598557
- Testing
- Exemestane, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States, Italy
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Lung Cancer
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
This is a 2-part prospective trial examining the ability of Stereotactic Body Radiation Therapy (SBRT) to induce a response to MK-3475, a humanized antibody to PD-1, in patients who progress on this antibody.
- Trial name
- NCT02407171
- Testing
- MK-3475, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Breast Cancer
Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer
The purpose of the study is to assess the benefit of oral panobinostat monotherapy given to women with HER2-negative locally recurrent or metastatic breast cancer.
- Trial name
- NCT00777049
- Testing
- Panobinostat
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Translational Research in Oncology
Melanoma (Skin)
Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma. PURPOSE: This phase II trial is studying how well riluzole works in treating patients with stage III or stage IV…
- Trial name
- NCT00866840
- Testing
- riluzole
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Rutgers, The State University of New Jersey
Cancer
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant.
- Trial name
- NCT00248547
- Testing
- aprepitant, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer
A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
This open-label, randomized crossover study evaluated the quality of life, efficacy, and safety of subcutaneous Herceptin (trastuzumab) injected either into the thigh or the upper arm of participants with early HER2-positive…
- Trial name
- LISAH (NCT01928615)
- Testing
- Trastuzumab - intravenous solution, Trastuzumab - subcutaneous solution, Chemotherapy
- Where
- 2 sites in Austria
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Advanced Breast Cancer
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
This study aimed at evaluating the safety and efficacy of everolimus plus exemestane in Chinese postmenopausal women with ER+ HER2- locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on…
- Trial name
- BOLERO-5 (NCT03312738)
- Testing
- Everolimus, Exemestane
- Where
- 15 sites in China
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01031446
- Testing
- cisplatin, everolimus, paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00382070
- Testing
- Letrozole
- Where
- 806 sites in United States, Canada and 1 more
- Volunteers
- 3,966 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast…
- Trial name
- NCT01077154
- Testing
- Denosumab
- Where
- 459 sites in United States, Argentina and 37 more
- Volunteers
- 4,509 people
- Sponsor
- Amgen
Breast Cancer
Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Zoledronate may delay or prevent bone marrow metastases in patients with breast cancer. PURPOSE: This phase II trial is studying how well zoledronate works in treating bone marrow micrometastases in women with stage I…
- Trial name
- NCT00295867
- Testing
- Zoledronic Acid
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of California, San Francisco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.